share_log

ARS: Annual Report to Security Holders

ARS: Annual Report to Security Holders

ARS：年度报告
美股sec公告 ·  04/26 07:13
Moomoo AI 已提取核心信息
Cingulate Inc., a biopharmaceutical company, reported its financial results for the fiscal year ended December 31, 2023. The company, which focuses on developing products for conditions like ADHD, has not generated revenue and continues to incur losses. For 2023, the net loss was $23.5 million, an increase from the $17.7 million loss in 2022. The company's cash and cash equivalents stood at $52,416 at year-end, down from $5.3 million the previous year. Cingulate raised funds through various means, including a public offering, private placement, and debt conversion. The company's future plans involve seeking additional capital to support operations and product development. Cingulate's stock is listed on the NASDAQ Capital Market, and it faces the risk of delisting if it fails to meet the exchange's continued listing requirements. The company's financial statements have been prepared on a going concern basis, but there is substantial doubt about its ability to continue due to its financial condition.
Cingulate Inc., a biopharmaceutical company, reported its financial results for the fiscal year ended December 31, 2023. The company, which focuses on developing products for conditions like ADHD, has not generated revenue and continues to incur losses. For 2023, the net loss was $23.5 million, an increase from the $17.7 million loss in 2022. The company's cash and cash equivalents stood at $52,416 at year-end, down from $5.3 million the previous year. Cingulate raised funds through various means, including a public offering, private placement, and debt conversion. The company's future plans involve seeking additional capital to support operations and product development. Cingulate's stock is listed on the NASDAQ Capital Market, and it faces the risk of delisting if it fails to meet the exchange's continued listing requirements. The company's financial statements have been prepared on a going concern basis, but there is substantial doubt about its ability to continue due to its financial condition.
生物制药公司Cingulate Inc. 公布了截至2023年12月31日的财年财务业绩。该公司专注于开发针对注意力缺陷多动障碍等疾病的产品，但尚未创造收入，并且继续蒙受损失。2023年，净亏损为2350万美元，较2022年的1770万美元亏损有所增加。截至年底，该公司的现金及现金等价物为52,416美元，低于去年的530万美元。Cingulate通过各种方式筹集资金，包括公开发行、私募和债务转换。该公司的未来计划包括寻求额外资金以支持运营和产品开发。Cingulate的股票在纳斯达克资本市场上市，如果未能满足该交易所的持续上市要求，它将面临退市的风险。该公司的财务报表是在持续经营的基础上编制的，但由于其财务状况，其持续经营能力存在重大疑问。
生物制药公司Cingulate Inc. 公布了截至2023年12月31日的财年财务业绩。该公司专注于开发针对注意力缺陷多动障碍等疾病的产品，但尚未创造收入，并且继续蒙受损失。2023年，净亏损为2350万美元，较2022年的1770万美元亏损有所增加。截至年底，该公司的现金及现金等价物为52,416美元，低于去年的530万美元。Cingulate通过各种方式筹集资金，包括公开发行、私募和债务转换。该公司的未来计划包括寻求额外资金以支持运营和产品开发。Cingulate的股票在纳斯达克资本市场上市，如果未能满足该交易所的持续上市要求，它将面临退市的风险。该公司的财务报表是在持续经营的基础上编制的，但由于其财务状况，其持续经营能力存在重大疑问。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息